BEDFORD, Ohio, Dec. 26 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories Inc., announced that it will begin marketing Ondansetron Injection USP as of December 26, 2006. This product is AP rated and is equivalent to Zofran(R) by GlaxoSmithKline. Ondansetron Injection USP is indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. It is also indicated for prevention of postoperative nausea and/or vomiting.
"As part of our objective to offer an extensive selection of specialty products to meet the changing needs of healthcare professionals, we are pleased to announce the addition of Ondansetron Injection USP to our portfolio," said David Gaugh, General Manager of Bedford Laboratories.
Bedford Laboratories will supply Ondansetron Injection USP, 2mg/mL packaged in 4mg/2mL single-dose vials and 40mg/20mL multi-dose vials. Prescribing information is available upon request from the Bedford Laboratories' professional services department, (800) 521-5169, or from the company's web site, http://www.bedfordlabs.com.
Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and approximately 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of US $11.8 billion (9.5 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information please visit http://www.boehringer-ingelheim.com
Bedford LaboratoriesCONTACT: Jason Kurtz of Bedford Laboratories, 1-800-562-4797, ext 3668